Humana shares fell sharply this week even as TD Cowen upgraded the stock to Buy and raised its price target to $485, underscoring how the insurer’s next move will depend less on near-term volatility and more on whether it can translate 2026 underwriting pressure into a better earnings reset.
Humana Stock Falls After TD Cowen Raises Target
The upgrade matters because Humana sits at the center of a bruised Medicare Advantage market where investors have been rethinking margin durability, medical cost inflation and the impact of weaker star ratings. For a health insurer with heavy exposure to government-backed plans, the question is not just whether earnings recover, but how quickly premium pricing, benefit design and membership mix can catch up with a tougher cost environment.
That backdrop helps explain the stock’s recent whipsaw. Humana closed at $380.00 on Nov. 19 after touching $461.25 two days earlier, a reminder that the shares remain highly sensitive to changes in sentiment around managed care. The stock is still well above its 200-day moving average of about $321, but it has lost momentum in recent sessions, with the relative strength index sliding to 40.1 and the MACD crossing lower, both signs of fading technical strength rather than a clean reversal in the underlying thesis.
Humana’s latest 10-Q already pointed to the strain. The company flagged a BY 2026 star ratings headwind, a development that can weigh on reimbursement and profitability in Medicare Advantage. At the same time, peer filings from UnitedHealth and Cigna have reinforced the broader industry message: health plans are facing higher care patterns, rising unit costs and more pressure to reprice coverage. That combination tends to hurt margins first and only later feed into higher premiums, making the next few quarters a balance-sheet-and-pricing story as much as an earnings one.
For investors, the upgrade is a call on timing. The bull case is that Humana’s selloff has already discounted much of the reimbursement and cost pressure, leaving room for upside if management stabilizes margins and proves it can protect enrollment. The bear case is that star-rating pressure and elevated medical utilization keep earnings under strain longer than expected, limiting multiple expansion even if the stock looks inexpensive relative to the recent high.
TD Cowen’s $485 target implies confidence that Humana can navigate that reset better than the market currently assumes. The near-term catalyst will be whether the company can show that 2026 pricing and product changes offset the earnings drag from ratings and medical costs. Until then, the stock is likely to trade on every signal about Medicare Advantage profitability, not just on the upgrade itself.
| Entity | Gains | Losses |
|---|---|---|
| TD Cowen | ▲Calls the turn early | ▼Risks looking premature |
| Humana bulls | ▲Re-rating potential | ▼Near-term volatility |
| Humana bears | ▲Cost and ratings concerns validated | ▼Thesis challenged by upgrade |
| Medicare Advantage rivals | ▲Industry repricing tailwind | ▼Margin pressure remains broad |



